• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gilead Sciences (NQ: GILD )

    63.15 -1.12 (-1.74%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,684,572
    Open 64.17
    Bid (Size) 63.16 (1)
    Ask (Size) 63.35 (2)
    Prev. Close 64.27
    Today's Range 62.69 - 64.34
    52wk Range 62.07 - 87.86
    Shares Outstanding 1,253,809,440
    Dividend Yield 4.75%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
    Via InvestorPlace
    Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
    The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
    Via Investor's Business Daily

    Performance

    YTD
    -24.14%
    -24.14%
    1 Month
    -7.00%
    -7.00%
    3 Month
    -13.98%
    -13.98%
    6 Month
    -20.56%
    -20.56%
    1 Year
    -18.74%
    -18.74%

    More News

    Read More
    Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
    Via Benzinga
    Topics Death
    Exposures Death
    Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
    Via Investor's Business Daily
    What 8 Analyst Ratings Have To Say About Gilead Sciences
    Via Benzinga
    $100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
    Via Benzinga
    New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
    From Gilead Sciences, Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    3 Stocks With Mouthwatering Dividends You Can Buy Right Now
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
    From Gilead Sciences, Inc.
    Via Business Wire
    Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
    Via The Motley Fool
    The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
    Via InvestorPlace
    7 Dividend Stocks to Invest In for a Lifetime of Income
    Via InvestorPlace
    Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
    From Gilead Sciences, Inc.
    Via Business Wire
    National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
    Via Benzinga
    3 Dividend Stocks That Even Ken Griffin Is Buying
    Via InvestorPlace
    Large Cap BIopharmaceuticals Overview
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
    Via Benzinga
    Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    From Gilead Sciences, Inc.
    Via Business Wire
    Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
    Via Benzinga
    EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
    From Gilead Sciences, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.